Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck's Sugammadex Sails Through FDA Panel But Faces Post-Approval Studies

This article was originally published in The Pink Sheet Daily

Executive Summary

Advisory committee suggests post-marketing epidemiological studies in higher risk patients to further assess risks of hypersensitivity, anaphylaxis and cardiac rhythm disorders with the neuromuscular blockade reversal agent.

Advertisement

Related Content

Merck's Bridion Approval Carries Several Post-Market Requirements
Sugammadex Review: Has Merck Finally Put Safety Concerns To Rest?
Schering-Plough’s Bridion Makes Positive Impression On Advisory Panel

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS078060

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel